HANGZHOU TIGERMED CO. H 1 (F:5HZ1) — Market Cap & Net Worth
Market Cap & Net Worth: HANGZHOU TIGERMED CO. H 1 (5HZ1)
HANGZHOU TIGERMED CO. H 1 (F:5HZ1) has a market capitalization of $618.97 Million (€529.44 Million) as of May 2, 2026. Listed on the F stock exchange, this Germany-based company holds position #11449 globally and #1275 in its home market, demonstrating a -4.87% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HANGZHOU TIGERMED CO. H 1's stock price €4.30 by its total outstanding shares 123124800 (123.12 Million).
HANGZHOU TIGERMED CO. H 1 Market Cap History: 2021 to 2026
HANGZHOU TIGERMED CO. H 1's market capitalization history from 2021 to 2026. Data shows change from $889.77 Million to $618.97 Million (-14.56% CAGR).
HANGZHOU TIGERMED CO. H 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HANGZHOU TIGERMED CO. H 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 5HZ1 by Market Capitalization
Companies near HANGZHOU TIGERMED CO. H 1 in the global market cap rankings as of May 2, 2026.
Key companies related to HANGZHOU TIGERMED CO. H 1 by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
HANGZHOU TIGERMED CO. H 1 Historical Marketcap From 2021 to 2026
Between 2021 and today, HANGZHOU TIGERMED CO. H 1's market cap moved from $889.77 Million to $ 618.97 Million, with a yearly change of -14.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €618.97 Million | -5.29% |
| 2025 | €653.51 Million | +24.04% |
| 2024 | €526.84 Million | +2.42% |
| 2023 | €514.39 Million | -46.92% |
| 2022 | €969.12 Million | +8.92% |
| 2021 | €889.77 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of HANGZHOU TIGERMED CO. H 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $618.97 Million USD |
| MoneyControl | $618.97 Million USD |
| MarketWatch | $618.97 Million USD |
| marketcap.company | $618.97 Million USD |
| Reuters | $618.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HANGZHOU TIGERMED CO. H 1
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and to… Read more